Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER ‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs

(2020) Matteo Canale et al.   Journal of Clinical Medicine

Attenuation of p53 mutant as an approach for treatment Her2-positive cancer

(2020) Olga Fedorova et al.   Cell Death Discovery

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

(2019) Zongbi Yi et al.   BMC CANCER

Safety, Efficacy and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

(2019) Qiao Li et al.   CLINICAL CANCER RESEARCH

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer

(2019) Collins et al.   Cancers

Assessing tumor heterogeneity using ctDNA to predict and monitor therapeutic response in metastatic breast cancer

(2019) Fei Ma et al.   INTERNATIONAL JOURNAL OF CANCER

Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas

(2019) Lawrence A. Donehower et al.   Cell Reports

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC

(2019) Helei Hou et al.   Cancer Management and Research

Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

(2019) Fei Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib

(2019) Jun Zhao et al.   LUNG CANCER

WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer

(2019) Andrea Sand et al.   CANCER LETTERS

Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

(2018) Michael J. Duffy et al.   BREAST CANCER RESEARCH AND TREATMENT

Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells

(2018) Alisha Yallowitz et al.   Cell Death & Disease

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers

(2018) Pedram Razavi et al.   CANCER CELL

Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy

(2018) Siqing Fu et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

HER kinase inhibition in patients with HER2- and HER3-mutant cancers

(2018) David M. Hyman et al.   NATURE

Maftools: efficient and comprehensive analysis of somatic variants in cancer

(2018) Anand Mayakonda et al.   GENOME RESEARCH

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

(2018) Youjin Kim et al.   Journal of Thoracic Oncology

Mutant p53 as a target for cancer treatment

(2017) Michael J. Duffy et al.   EUROPEAN JOURNAL OF CANCER

Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2017) Fei Ma et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR -mutated non-small cell lung cancer (NSCLC)

(2017) Catherine Labbé et al.   LUNG CANCER

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis

(2017) Zongbi Yi et al.   Scientific Reports

Impact of TP53 Mutations on Outcome in EGFR -Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors

(2016) Matteo Canale et al.   CLINICAL CANCER RESEARCH

PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer

(2016) Charlotte Fribbens et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

A gain-of-function mutant p53–HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress

(2014) D Li et al.   Cell Death & Disease

p53 in breast cancer subtypes and new insights into response to chemotherapy

(2013) Philippe Bertheau et al.   BREAST